Catalog # LY1-H5255



Synonym

LYPD1,Ly6/PLAUR domain-containing protein 1,FLJ41033,LY6/PLAUR domain containing 1,LYPDC1,PHTS,Putative HeLa tumor suppressor

Source

Human LYPD1 Protein, Llama IgG2b Fc Tag(LY1-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 21 - Gly 115 (Accession # <u>Q8N2G4-1</u>).

Predicted N-terminus: Leu 21

Molecular Characterization

```
LYPD1(Leu 21 - Gly 115)
                   LlamaFc(Glu 1 - Ser 243)
Q8N2G4-1
                         AAX73259.1
```

This protein carries a llama IgG2b Fc tag at the C-terminus

The protein has a calculated MW of 38.2 kDa. The protein migrates as 47-52 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.01 EU per μ g by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human LYPD1 Protein, Llama IgG2b Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA

戻LYPD1 ELISA

Immobilized Human LYPD1 Protein, Llama IgG2b Fc Tag (Cat. No. LY1-H5255) at 1 μ g/mL (100 μ L/well) can bind Anti-LYPD1 antibody with a linear range of 0.02-0.625 μ g/mL (QC tested).

>>> www.acrobiosystems.com

8/14/2023

Catalog # LY1-H5255

ACTO

Background

Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety.

Clinical and Translational Updates

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.



8/14/2023